(Circulation. 1996;94:279-285.)
© 1996 American Heart Association, Inc.
Articles |
Platelet Activation and Coronary Stent Implantation
Effect of Antithrombotic Therapy
the First Medizinische Klinik der Technischen Universitat Munchen (Germany).
Correspondence to Dr med Meinrad Gawaz, First Medizinische Klinik, Technische Universitat Munchen, Ismaningerstr 22, 81675 Munchen, Germany.
Background Platelet activation and surface expression of adhesive glycoproteins play a key role in ischemic thrombotic complications after coronary intervention. The purpose of this case-control study was to evaluate the effects of two different antithrombotic regimens on platelet function after coronary Palmaz-Schatz stent implantation.
Methods and Results The study group consisted of 46 "low-risk" patients who were treated with ticlopidine (250 mg BID) and aspirin (100 mg BID) after stenting. The control group was derived from a cohort of 151 patients receiving conventional anticoagulation therapy, including phenprocoumon (target international normalized ratio, 3.5), heparin (activated partial thromboplastin time, 80 to 120 seconds), and aspirin (100 mg BID) after stenting. Criteria for matching were indication for stenting, target vessel, balloon size, inflation pressure, and number of inserted stents. Matches were obtained for 38 patients. Platelet function was evaluated before and daily for 12 days after stenting in venous blood samples with immunologic activation markers. Patients receiving anticoagulation therapy showed a significantly increased surface exposure of LIBS1 (activated fibrinogen receptor; P<.05) and CD62P (P-selectin; P<.001) above prestent values, peaking days 3 to 6 after stenting. In contrast, in patients receiving ticlopidine, expression of LIBS1 decreased (P<.01) and expression of CD62P remained basically unchanged after stenting. Platelet count significantly decreased after stenting in patients treated by anticoagulation (day 3; P<.01), whereas no significant changes were found in the ticlopidine group.
Conclusions Significant platelet activation occurs in patients receiving anticoagulation therapy after stenting, while platelet deactivation is found in patients treated with combined antiplatelet therapy. This may contribute to a lowering of the incidence of subacute stent thrombosis.
Key Words: angioplasty • stents • platelets • glycoproteins • ticlopidine
This article has been cited by other articles:
 |
|
 |
|
  M. Gawaz The evolving science of atherothrombotic disease Eur. Heart J. Suppl., November 1, 2008; 10(suppl_I): I4 - I7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Htun, S. Fateh-Moghadam, B. Tomandl, R. Handschu, K. Klinger, K. Stellos, C. Garlichs, W. Daniel, and M. Gawaz Course of Platelet Activation and Platelet-Leukocyte Interaction in Cerebrovascular Ischemia Stroke, September 1, 2006; 37(9): 2283 - 2287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Spahn, S. J. Howell, A. Delabays, and P.-G. Chassot Coronary stents and perioperative anti-platelet regimen: dilemma of bleeding and stent thrombosis. Br. J. Anaesth., June 1, 2006; 96(6): 675 - 677. [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. van der Zee, E. Biro, Y. Ko, R. J. de Winter, C. E. Hack, A. Sturk, and R. Nieuwland P-Selectin- and CD63-Exposing Platelet Microparticles Reflect Platelet Activation in Peripheral Arterial Disease and Myocardial Infarction Clin. Chem., April 1, 2006; 52(4): 657 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Serruys, M. J.B. Kutryk, and A. T.L. Ong Coronary-Artery Stents N. Engl. J. Med., February 2, 2006; 354(5): 483 - 495. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Claeys, M. G. Van der Planken, J. M. Bosmans, J. J. Michiels, F. Vertessen, P. Van Der Goten, F. L. Wuyts, and C. J. Vrints Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis Eur. Heart J., March 2, 2005; 26(6): 567 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.-S. Huang, C.-Y. Li, P.-C. Hsu, C.-S. Tsai, T.-C. Lin, and C.-S. Wong Sevoflurane Anesthesia Attenuates Adenosine Diphosphate-Induced P-Selectin Expression and Platelet-Leukocyte Conjugate Formation Anesth. Analg., October 1, 2004; 99(4): 1121 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Kapadia, C. T. Bajzer, K. M. Ziada, D. L. Bhatt, O. M. Wazni, M. J. Silver, E. G. Beven, K. Ouriel, and J. S. Yadav Initial Experience of Platelet Glycoprotein IIb/IIIa Inhibition With Abciximab During Carotid Stenting: A Safe and Effective Adjunctive Therapy Stroke, October 1, 2001; 32(10): 2328 - 2332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Atalar, K. Aytemir, I. Haznedaroglu, S. Aksoyek, K. Ovunc,, S. Kirazli, and F. Ozmen Platelet and Leukocyte Deactivation After Intracoronary Stent Placement in Patients Receiving Combined Antiplatelet Therapy Clinical and Applied Thrombosis/Hemostasis, April 1, 2001; 7(2): 116 - 121. [Abstract] [PDF]
|
|
|
|
|
|
B Scheller, B Hennen, A Pohl, H Schieffer, and T Markwirth Acute and subacute stent occlusion; risk-reduction by ionic contrast media Eur. Heart J., March 1, 2001; 22(5): 385 - 391. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Merten, T. Chow, J. D. Hellums, and P. Thiagarajan A New Role for P-Selectin in Shear-Induced Platelet Aggregation Circulation, October 24, 2000; 102(17): 2045 - 2050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Moshfegh, M. Redondo, F. Julmy, W. A. Wuillemin, M. U. Gebauer, A. Haeberli, and B. J. Meyer Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy J. Am. Coll. Cardiol., September 1, 2000; 36(3): 699 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Alt, I. Haehnel, C. Beilharz, K. Prietzel, D. Preter, A. Stemberger, T. Fliedner, W. Erhardt, and A. Schomig Inhibition of Neointima Formation After Experimental Coronary Artery Stenting : A New Biodegradable Stent Coating Releasing Hirudin and the Prostacyclin Analogue Iloprost Circulation, March 28, 2000; 101(12): 1453 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Wehinger, A. Kastrati, S. Elezi, H. Baum, S. Braun, F.-J. Neumann, and A. Schomig Lipoprotein(a) and coronary thrombosis and restenosis after stent placement J. Am. Coll. Cardiol., March 15, 1999; 33(4): 1005 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gawaz, F.-J. Neumann, and A. Schomig Evaluation of Platelet Membrane Glycoproteins in Coronary Artery Disease : Consequences for Diagnosis and Therapy Circulation, January 12, 1999; 99 (1): e1 - e11. [Full Text] [PDF]
|
|
|
|
|
|
J. K. Mickelson, M. N. Ali, N. S. Kleiman, N. M. Lakkis, T. W. Chow, B. J. Hughes, and C. W. Smith Chimeric 7e3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty J. Am. Coll. Cardiol., January 1, 1999; 33(1): 97 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Steinhubl, M. S. Lauer, D. P. Mukherjee, D. J. Moliterno, A. M. Lincoff, S. G. Ellis, and E. J. Topol The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1366 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.M. ten Berg, H.W.M. Plokker, A. Kastrati, F.J. Neumann, and A. Schomig Effect of Warfarin on Rate of Restenosis After PTCA • Response Circulation, May 26, 1998; 97(20): 2097 - 2098. [Full Text]
|
|
|
|
|
|
H. J. Rupprecht, H. Darius, U. Borkowski, T. Voigtlander, B. Nowak, S. Genth, and J. Meyer Comparison of Antiplatelet Effects of Aspirin, Ticlopidine, or Their Combination After Stent Implantation Circulation, March 24, 1998; 97(11): 1046 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Platelet Activation After Stenting Journal Watch Cardiology, November 1, 1996; 1996(1101): 13 - 13. [Full Text]
|
|